Randomized Trialhigh evidence
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
The New England journal of medicine·April 3, 2025·PMID 39602624
Why it mattersLenacapavir offers a highly effective, infrequent dosing option for PrEP in populations where daily pill adherence can be challenging, potentially improving real-world prevention outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled